Single Cell Multiomics Market is Segmented By Type (Single Cell Genomics, Single Cell Proteomics, Single Cell Transcriptomics, Single Cell Metabolomics), By Application (Oncology, Cell Biology, Neurology, Immunology, Stem Cell Research), By Technique (Single-Cell Isolation & Dispensing, Single-Cell Analysis), By End User (Academic Institutes, Contract Research Organization, Phamaceutical & Biotech Companies, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Single cell multiomics market size was valued at US$ YY million in 2023 and is estimated to reach US$ YY million by 2031, growing at a CAGR of 21.2% during the forecast period (2024-2031).
Single-cell multi-omics technologies often assess numerous types of molecules from a single cell, providing greater in-depth biological knowledge than can be obtained by examining each molecular layer from separate cells. Unlike live-cell fluorescence imaging, which requires the destruction of cells for analysis, single-cell multimodal omics (scMulti-omics) technologies allow the measurement of multiple modalities from the same cell, including DNA methylation, chromatin accessibility, RNA expression, protein abundance, gene perturbation, and spatial information.
Single Cell Multiomics Market Scope
| Metrics | Details |
| Market CAGR | 21.2% |
| Segments Covered | By Type, By Application, By Technique, By End User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Get a Free Sample Click here
Single Cell Multiomics Market Dynamics
To comprehend the interplay of molecules, integrated approaches combine individual omics data sequentially or simultaneously. The genotypic and phenotypic classifications of single-cell sequencing technology aid in determining the mechanisms that govern diseases and health. Oncology, cell biology, neurology, stem cell, and immunology are among the most common single-cell multi-omics market applications. Single-cell omics has immense promise for understanding virus biology and virus-host cell interactions, making it a valuable virology tool that should be employed more frequently.
Technological developments in single-cell analysis products will drive the market growth
Technological developments in single-cell analysis products and an increase in the number of large-scale genomics research using single-cell RNA sequencing are driving the expansion of the single-cell multi-omics market (sc-RNA). Furthermore, rising disposable income in emerging countries and increased adoption of customized medicine for genetic condition screening and diagnosis are propelling the single-cell multi-omics market forward. Personalized therapy can simplify these illnesses' clinical and molecular complexity, which are linked to high mortality and high healthcare costs. Furthermore, this could provide useful tools for preventive tactics and probable indications about the disease's progression, and it could help forecast morbidity, mortality, and chronic disease indicators far earlier in the disease's course.
Furthermore, new single-cell platforms make isolation and analysis easier. In some situations, both the potential development and limitations of these technologies are fast being created, sparking greater interest among academics, notably in single-cell genomics. As a result, technical developments in single-cell analysis products are likely to accelerate the growth of the single-cell multi-omics market.
Furthermore, the expansion of various initiatives and collaborations between pharmaceutical and biotechnology firms and research institutes is important in driving the market growth. Increased collaborations and financing in single-cell multi-omics research and expansion into new research applications like single-cell metabolomics are expected to present lucrative growth possibilities for single-cell multi-omics market players. Large-scale biotech manufacturing facilities cost US$ 200 million to US$ 500 million or more to establish, although similar-scale small-molecule facilities may cost only US$ 30 million to US$ 100 million. Rapid expansion and the industry's growing prominence create new problems and opportunities. The advancement and development of next-generation sequencing techniques for the diagnosis of oncology, immunology, and other diseases are the primary driving force behind the growth of the worldwide single-cell multi-omics market. According to the World Health Organization (WHO), effective and early treatment of infectious disease can increase national productivity by up to 20% while improving personal health. Furthermore, non-invasive diagnosis is a sophisticated technology that overcomes the barrier of heterogeneity associated with bulk cell populations, which raises the requirement for non-invasive diagnosis and is a driving force in the target market's growth.
Furthermore, the industry has been propelled by a significant increase in healthcare expenditures worldwide. The rise in population, particularly geriatrics, and greater medical service consumption for early diagnosis of genetic abnormalities are two main factors driving up healthcare costs. These factors are likely to boost the single cell multiomics market.
The high cost of single-cell analysis is likely to hamper the market growth
The high cost of single-cell analysis and the scarcity of large online data storage and analysis platforms, on the other hand, is projected to constrain market expansion.
COVID-19 Impact Analysis
The COVID-19 outbreak is expected to boost the single-cell multi-omics industry. Many clinics and hospitals around the world have been reconfigured to boost hospital capacity for COVID-19 patients. Due to the substantial increase in COVID-19 cases, non-essential procedures may face a backlog. Manufacturing and shipping of healthcare essentials were both disrupted due to the shutdown. Other issues influencing the market include:
- A lack of medical treatment.
- A shortage of healthcare workers.
- An increase in COVID-19-related hospitalizations.
Additionally, single-cell multi-omics has positively impacted a variety of healthcare services. According to healthcare professionals, the single-cell multi-omics market is one of the most rapidly evolving markets. Furthermore, the global market is being driven by chronic disorders such as cancer and infectious diseases caused by viruses. The research into single-cell multi-omics for COVID-19 could help the target market grow. As a result of enhanced healthcare infrastructure, more personalization of medications increased unmet healthcare requirements and increased R&D activity. Furthermore, significant technical breakthroughs for early illness diagnosis present a new opportunity for important players to engage in the single-cell multi-omics market.
Single Cell Multiomics Market Segment Analysis
The oncology segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
Due to an increase in cancer incidence globally, the need for personalized treatments, and a surge in early diagnosis and screening among the population, the oncology category held the biggest market share in 2020 and is likely to stay dominant over the forecast period.
In the United States, a projected 1,806,590 new cancer cases will be identified in 2020, with 606,520 people dying from the disease.Breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer are the most common cancers (listed in descending order by estimated new cases in 2020).(Source: Nation Cancer Institute).
Single Cell Multiomics Market Geographical Analysis
North America region holds the largest market share of the global single cell multiomics market
North America is expected to account for a sizable portion of the worldwide single-cell omics market during the forecast period. The region's market is expected to increase rapidly soon, owing mostly to the availability of sophisticated health care infrastructure and ongoing research initiatives to develop innovative technologies in the region. During the projection period, North America is expected to follow Europe. In addition, organic and inorganic strategies such as mergers and acquisitions and partnerships within key market players will strengthen their product portfolio in the studied market which will drive the market. Also, several product launches in the market will lead to lucrative growth of the market.For instance in November 2019, QIAGEN has introduced QIA seq Multimodal Panels, designed for consolidated tailored DNA and RNA enrichment and analysis.Furthermore, advanced healthcare infrastructure is expected to drive the growth of the Single Cell Multiomics market in North America.
Single Cell Multiomics Market Competitive Landscape
The single cell multiomics market is a fiercely competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include 10 X Genomics Inc, BD Biosciences, Berkeley Lights Inc, Cytena, Dolomite Bio, Fluidigm Corporation, Illimina Inc, Nanostring Technologies Inc, Qiagen NV, Takara Holdings Inc, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Single Cell Multiomics market globally. For instance, In July 2019, QIAGEN collaborated with Illumina to expand the availability and use of NGS-based in vitro diagnostic (IVD) kits.
NanoString Technologies Inc
Overview:
NanoString Technologies is a publicly-traded company that manufactures life science equipment for translational research. The technology used by the company provides a wide range of fundamental research and translational medicine applications.NanoString's products are based on a revolutionary digital molecular barcoding technique developed at Dr. Leroy Hood's Institute for Systems Biology (ISB) in Seattle. In 2003, the company was created with an exclusive license to develop and market the technology. With its initial multiplexed assays for gene expression analysis, NanoString developed its first commercial instrument set and began international sales activities in 2008. In 2010, the company released new system applications to facilitate microRNA analysis and copy number variation detection.
Product Portfolio:
CosMx SMI: CosMx SMI is the first high-plex in situ analysis platform to enable spatial multi-omics at the cellular and subcellular resolution with formalin-fixed paraffin-embedded (FFPE) and fresh frozen (FF) tissue samples. CosMx SMI allows for the fast quantification and visualization of up to 1,000 RNA and 100 verified protein analytes. The adaptable, spatial single-cell imaging technology will enable a greater understanding of cell atlas, tissue phenotyping, cell-cell interactions, cellular processes, and biomarker development.
Frequently Asked Questions
What is the Projected CAGR value of the Single Cell Multiomics Market?
Single Cell Multiomics Market is expected to grow at a CAGR of 21.2% during the forecasting period 2024-2031.
Which region controlled the global market during 2024-2031?
North America region Controls the Single Cell Multiomics Market during 2024-2031
Which is the fastest growing region in the Single Cell Multiomics Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period.
